Of particular importance, the ADAM-15-mediated cleavage and release of sE-cad stimulates the Human epidermal growth factor receptor 2 (Her2/neu), a transmembrane protein overexpressed in 20%–25% of breast cancer patients. Here, ERBB2 is linked to breast cancer.